Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal Weight rating on the shares. The company posted a Q4 beat and gave first time 2025 revenue and expense guidance that bracketed consensus, notes the analyst, who adds that the focus looking ahead is on the Journavx and Alyftrek launches.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Mixed Financial Performance and Future Prospects Lead to Hold Rating
- Vertex Pharmaceuticals: Hold Rating Due to Mixed Outlook and Generic Competition Risks
- Vertex Pharmaceuticals price target raised to $467 from $435 at Barclays
- Vertex Pharmaceuticals (VRTX) Sees Strong 2025 Revenue Growth
- Positive Outlook for Vertex Pharmaceuticals: Strong Cystic Fibrosis Performance and Promising Product Launches Drive Buy Rating